Oral-Azacitidine is a medication used in this clinical trial to help treat a type of blood cancer called acute myeloid leukemia (AML). It works by interfering with the growth of cancer cells, which can help to slow down or stop the progression of the disease. In this study, oral-azacitidine is being tested to see how well it works when combined with another medication, gilteritinib, for patients whose cancer has returned or has not responded to previous treatments.

Gilteritinib is another medication used in this trial, specifically for patients with a type of acute myeloid leukemia that has a mutation in the FLT3 gene. This medication targets and blocks the activity of the FLT3 protein, which is often involved in the growth and survival of cancer cells. By inhibiting this protein, gilteritinib can help to reduce the number of cancer cells in the body. The trial is investigating how effective gilteritinib is when used together with oral-azacitidine for treating this specific type of leukemia.

Acute Myeloid Leukemia with FLT3 Mutation – Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells. In cases with FLT3 mutation, there is a specific genetic alteration that leads to the uncontrolled proliferation of these cells. The disease progresses as these abnormal cells accumulate, interfering with the production of normal blood cells. This can lead to symptoms such as fatigue, frequent infections, and easy bruising or bleeding. Over time, the bone marrow becomes increasingly filled with these leukemia cells, further reducing the body’s ability to produce healthy blood cells. The progression of the disease can vary, but it typically involves a worsening of symptoms as the number of leukemia cells increases.